Immunex Message Board - Msg: 2183868

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rich evans who wrote (88)	9/12/1997 7:53:00 PM
From: The Thrifty Investor	of 656

Rich, I believe that your assumption of $100 per year for Enbrel is wrong. Rheumatoid Arthritis is a cripling disease. There are presently no drugs available to help except general over the counter pain relievers. Asthma drugs can cost around $50 per month and there is lots of competition. It is not unreasonable to expect Immunex to make $600 * 1.5 million = $900 million in revenues * 50% profit margin = $450 million in profit. $450 million / 40 million shares gives an $11.25 mature EPS. Add to this a nice pipeline and by the year 2000 this company could be worth about $200 per share. DLJ gave a 1 year target price of $120 on IMNX today. This is the second time I've owned IMNX. I owned the shares back in the 1992-1993 timeframe and enjoyed a nice runup back then. Hopefully, my pleasant experience will be repeated. Best Regards, The Thrifty Investor

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next